beeldscherm schreef op 17 mei 2018 08:34:
[...]
zei Hans Anders,
Outlook
For the remainder of 2018, the Company expects:
• Continued growth in revenues from sales of RUCONEST®, mainly driven by the US
operations.
• Achievement of positive quarterly operating results and net results throughout the course
of the year.
• Continued investment in the production of RUCONEST® in order to ensure continuity of
supply to the growing markets in the US, Europe and the rest of the world.
• Investment in RUCONEST® in prophylaxis of HAE (following approval) and in the
development of new intramuscular and subcutaneous versions of RUCONEST®.
• Investment in clinical trial development for RUCONEST® in other indications where the
drug’s unique properties may help solve unmet medical needs.
We will also continue to invest in our pipeline programs in Pompe disease and Fabry’s
disease, and will look to acquire additional development opportunities and assets as they
occur.
• Increasing marketing activity where profitable for Pharming, such as in our current major
territories of the USA and in Europe: Austria, France, Germany, the Netherlands and the UK.
• We will continue to support patients in all territories, as we continue to believe that
RUCONEST® represents a fast, effective, reliable and safe therapy option for HAE patients.